Literature DB >> 9222561

Pharmacological characterization of the vanilloid receptor in the rat dorsal spinal cord.

K A Wardle1, J Ranson, G J Sanger.   

Abstract

1. In the present study a novel 96-well plate assay system was used to characterize pharmacologically the vanilloid receptor in the dorsal spinal cord of the rat. When activated, this receptor stimulates release of calcitonin gene-related peptide (CGRP) from the central terminals of the afferent nerves. 2. Capsaicin, resiniferatoxin (RTX) and olvanil each evoked a concentration-dependent increase in CGRP release with pEC50 values of 6.55 +/- 0.07, 7.90 +/- 0.24 and 6.19 +/- 0.15 respectively. RTX and olvanil were partial agonists with respect to capsaicin. All concentration-effect curves were bell-shaped. 3. The vanilloid receptor antagonist, capsazepine (10 microM) had no effect on basal peptide release but inhibited the CGRP release evoked by all 3 agonists to a similar extent. These results suggest that the antagonistic effects of capsazepine were agonist-independent. 4. The capsaicin-sensitive cation channel blocker, ruthenium red (10 microM) had no effect on basal CGRP release, but antagonized the peptide release evoked by capsaicin, olvanil and RTX. 5. The pharmacology of the vanilloid receptor in the rat dorsal spinal cord is not identical to that previously found in other systems. The reason for these differences is unclear, but the possibility of multiple classes of receptor cannot at this stage be ruled out.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9222561      PMCID: PMC1564762          DOI: 10.1038/sj.bjp.0701199

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  The proteinase-activated receptor 2 is involved in nociception.

Authors:  W A Hoogerwerf; L Zou; M Shenoy; D Sun; M A Micci; H Lee-Hellmich; S Y Xiao; J H Winston; P J Pasricha
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

2.  Lack of sensorial innervation in the newborn female rats affects the activity of hypothalamic monoaminergic system and steroid hormone secretion during puberty.

Authors:  Ubaldo Quiróz; Leticia Morales-Ledesma; Carolina Morán; Angélica Trujillo; Roberto Domínguez
Journal:  Endocrine       Date:  2014-06       Impact factor: 3.633

3.  Respiratory actions of vanilloid receptor agonists in the nucleus of the solitary tract: comparison of resiniferatoxin with non-pungent agents and anandamide.

Authors:  Dominic P Geraghty; Stuart B Mazzone
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

4.  Altered pharmacology of native rodent spinal cord TRPV1 after phosphorylation.

Authors:  A J Mogg; C E J Mill; E A Folly; R E Beattie; M J Blanco; J P Beck; L M Broad
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

5.  Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin.

Authors:  Michela Rigoni; Marcello Trevisani; David Gazzieri; Riccardo Nadaletto; Michele Tognetto; Christophe Creminon; John B Davis; Barbara Campi; Silvia Amadesi; Pierangelo Geppetti; Selena Harrison
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 6.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

Review 7.  Transient receptor potential vanilloid channels in hypertension, inflammation, and end organ damage: an imminent target of therapy for cardiovascular disease?

Authors:  Donna H Wang
Journal:  Curr Opin Cardiol       Date:  2008-07       Impact factor: 2.161

8.  Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay.

Authors:  H-J Behrendt; T Germann; C Gillen; H Hatt; R Jostock
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

9.  The protective effect of genistein postconditioning on hypoxia/reoxygenation-induced injury in human gastric epithelial cells.

Authors:  Yu Li; Jian-fu Zhang; Yong-mei Zhang; Xiao-bo Ma
Journal:  Acta Pharmacol Sin       Date:  2009-04-06       Impact factor: 6.150

10.  TRPV1: a target for next generation analgesics.

Authors:  Louis S Premkumar; Parul Sikand
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.